HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge.

Abstract
Heparin, a potent anticoagulant used for the prevention of venous thromboembolism, has been recognized as a tumor angiogenesis inhibitor. Its limitation in clinical application for cancer therapy, however, arises from its strong anticoagulant activity, which causes associated adverse effects. In this study, we show the structural correlation of LHT7, a previously developed heparin-based angiogenesis inhibitor, with its influence on VEGF blockade and its decreased anticoagulant activity. LHT7 was characterized as having average seven molecules of sodium taurocholates conjugated to one molecule of low-molecular-weight heparin (LMWH). This study showed that the conjugation of sodium taurocholates selectively blocked interaction with antithrombin III (ATIII) while enhancing the binding with VEGF. This resulted in LHT7 to have negligible anticoagulant activity but potent anti-angiogenic activity. Following up on this finding, we showed that the bidirectional effect of sodium taurocholate conjugation was due to its unique structure, that is, the sterane core hindering the ATIII-binding pentasaccharide unit of LMWH with its bulky and rigid structural characteristics while the terminal sulfate group interacts with VEGF to produce stronger binding. In addition, we showed that LHT7 was localized in the tumor, especially on the endothelial cells. One explanation for this might be that LHT7 was delivered to the tumor via platelets.
AuthorsSeung Woo Chung, Myungjin Lee, Sang Mun Bae, Jooho Park, Ok Cheol Jeon, Hui Sun Lee, Han Choe, Han Sung Kim, Beom Suk Lee, Rang-Woon Park, Sang Yoon Kim, Youngro Byun
JournalBiomaterials (Biomaterials) Vol. 33 Issue 35 Pg. 9070-9 (Dec 2012) ISSN: 1878-5905 [Electronic] Netherlands
PMID23010574 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.
Chemical References
  • Angiogenesis Inhibitors
  • Anions
  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Oligosaccharides
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Taurocholic Acid
  • Antithrombin III
Topics
  • Angiogenesis Inhibitors (pharmacology)
  • Anions (chemistry)
  • Anticoagulants (pharmacology)
  • Antithrombin III (antagonists & inhibitors, chemistry)
  • Cell Line, Tumor
  • HT29 Cells
  • Heparin, Low-Molecular-Weight (chemistry, pharmacology)
  • Humans
  • Neovascularization, Pathologic
  • Oligosaccharides (antagonists & inhibitors, chemistry)
  • Taurocholic Acid (chemistry)
  • Vascular Endothelial Growth Factor A (chemistry)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: